A novel Nogo-66 receptor antagonist peptide promotes neurite regeneration in vitro

A novel Nogo-66 receptor antagonist peptide promotes neurite regeneration in vitro
复制标题

一种新型Nogo-66受体拮抗剂肽在体外促进神经突再生

DOI:
10.1016/j.mcn.2015.12.011
复制
发表时间:
2016-03
影响因子:
3.5
通讯作者:
Fei Xiao
Fei Xiao
中科院分区:
医学3区
文献类型:
--
作者:
Zhongqing Sun;Xiaoyong Dai;Yu Li;Shuwen Jiang;Guofeng Lou;Qiaoyu Cao;Rendong Hu;Yadong Huang;Zhijian Su;Meiwan Chen;Huanmin Luo;Xi Lin;Jun Sun;Fei Xiao

文献摘要

参考文献

相似文献

Nogo-66 受体 (NgR1) 是 Nogo-A 的一种受体,有助于抑制成人中枢神经系统创伤后的轴突再生。因此,NgR1 被认为是轴突再生治疗的关键靶点。在这里,我们从噬菌体展示七肽库中鉴定出一种特定的 NgR1 拮抗肽(HIYTALV,命名为 NAP2),它可以促进体外神经突再生。通过免疫荧光测定,NAP2 与 NgR1 共定位于 PC12 细胞和小脑颗粒细胞 (CGC) 的表面。辣根过氧化物酶(HRP)-链霉亲和素-生物素测定进一步表明,NAP2 与 NgR1 结合,解离常数(Kd)为 0.45 μM。功能分析表明,NAP2 可以通过阻断 Nogo-66 诱导的神经突生长来降低 Nogo-66 对分化 PC12 细胞和 CGC 神经突生长的抑制作用。 Rho 相关卷曲螺旋蛋白激酶 (ROCK)、塌陷素反应介导蛋白 2 (CRMP2) 和肌球蛋白轻链 (MLC)。综上所述,小分子NgR1拮抗肽NAP2(MW:815.98Da)具有潜在的穿越血脑屏障的能力,将成为治疗脊髓损伤和神经退行性疾病的有前景的治疗药物。
The Nogo-66 receptor (NgR1), a receptor for Nogo-A, contributes to the inhibition of axonal regeneration in the adult central nervous systemafter traumatic injuries. Thus, NgR1 has been considered a critical target in axon regeneration therapy. Here, we identified a specific NgR1 antagonist peptide (HIYTALV, named NAP2) which promotes neurite regeneration in vitro froma phage display heptapeptide library. NAP2was co-localized with NgR1 on the surface of PC12 cells and cerebellar granule cells (CGCs) by immunofluorescence assay. Horseradish peroxidase (HRP)-streptavidin-biotin assay further showed that NAP2 binds to NgR1 and the dissociation constant (Kd) was 0.45 μM Functional analyses indicated that NAP2 could reduce the inhibitory effects of Nogo-66 on neurite outgrowth in differentiated PC12 cells and CGCs by blocking the Nogo-66-induced activation of Rhoassociated coiled coil-containing protein kinase (ROCK), collapsin response mediator protein 2 (CRMP2) and myosin light chain (MLC). Taken together, the smallmolecule NgR1 antagonist peptide NAP2 (MW: 815.98Da) has a potential ability in crossing blood brain barrier andwill be a promising therapeutic agent for the treatment of spinal cord injury and neurodegenerative diseases.
DOI: 10.1093/brain/aws100
发表时间: 2012-06-01
期刊: BRAIN
影响因子: 14.5
作者:
Petratos, Steven;Ozturk, Ezgi;Bernard, Claude C. A.
通讯作者: Bernard, Claude C. A.
DOI: 10.2165/00023210-200822110-00001
发表时间: 2008
期刊: CNS Drugs
影响因子: 6
作者:
M. Sano;H. Grossman;K. Dyk
通讯作者: M. Sano;H. Grossman;K. Dyk
Nogo-A/Nogo-A 受体在阿尔茨海默病中的功能
DOI: 10.1111/cns.12387
发表时间: 2015
影响因子: 5.5
作者:
Yingqi Xu;Zhongqing Sun;Yitao Wang;Fei Xiao;Meiwan Chen
通讯作者: Meiwan Chen
DOI: 10.1073/pnas.1217665110
发表时间: 2013-04-16
影响因子: 11.1
作者:
Tews, Bjoern;Schoenig, Kai;Bartsch, Dusan
通讯作者: Bartsch, Dusan
DOI: 10.1016/j.conb.2014.02.011
发表时间: 2014-08
影响因子: 5.7
作者:
Schwab ME;Strittmatter SM
通讯作者: Strittmatter SM